The 50-day moving average for CME moved below the 200-day moving average on June 07, 2022. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 69 cases where CME's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CME declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
CME broke above its upper Bollinger Band on June 21, 2022. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CME's RSI Oscillator exited the oversold zone, of 18 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on June 17, 2022. You may want to consider a long position or call options on CME as a result. In of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for CME just turned positive on May 25, 2022. Looking at past instances where CME's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .
CME moved above its 50-day moving average on July 01, 2022 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CME crossed bullishly above the 50-day moving average on June 29, 2022. This indicates that the trend has shifted higher and could be considered a buy signal. In of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CME advanced for three days, in of 354 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 263 cases where CME Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 74, placing this stock better than average.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CME’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.647) is normal, around the industry mean (4.117). P/E Ratio (26.738) is within average values for comparable stocks, (48.652). CME's Projected Growth (PEG Ratio) (5.660) is very high in comparison to the industry average of (2.574). Dividend Yield (0.019) settles around the average of (0.038) among similar stocks. P/S Ratio (15.337) is also within normal values, averaging (94.834).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
an operator of securities and commodity exchanges
A.I.dvisor indicates that over the last year, CME has been closely correlated with ICE. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if CME jumps, then ICE could also see price increases.
|ICE - CME|
|NDAQ - CME|
|SCHW - CME|
|RJF - CME|
|MCO - CME|